December 2017
Julian Praceus presents the concept of an AI & Cloud-based platform for structural heart interventions in the ICI Start-up Competition in Tel-Aviv.
May 2018
LARALAB's first generation of Deep Learning segmentations from Cardiac CT indicates potential performance beyond-state-of-the-art.
August 2018
Founders Julian Praceus, Alex Vasilev and Julian Bernard kick-off LARALAB's business with the first one-room office in Munich.
October 2018
LARALAB was selected for the Philips Global AI start-up program from 700 start-ups: the only one in a pre-funding stage.
March 2019
heart.ai is used in R&D and early trial stages of three Mitral & Tricuspid devices.
June 2019
Julian Praceus presents a new decision-support concept for Mitral & Tricuspid interventions at CSI Frankfurt.
November 2019
LARALAB successfully completes proof-of-concept for automatic algorithms in collaboration with Prof. Dr. Jeffrey J. Popma and Dr. Felix Kreidel.
_edited.jpg)
January 2020
LARALAB closes Series A financing round with the goal to bring the LARALAB Platform to the market.
September 2020
LARALAB grows to a competitive team of 10.
November 2020
LARALAB appoints Dr. Peter Vorländer, former Philips Innovation Lead and Managing Director Philips Medical Systems GmbH to LARALAB's Board.
October 2021
LARALAB wins Munich Marathon Team Competition.
November 2021
heart.ai gets Quality Management System certified by TÜV Süd, in accordance with ISO 13485 and Medical Device Regulation (MDR) 2017/745.
May 2022
heart.ai receives CE marking under MDR along with its tricuspid valve workflow.
May 2022
The CE-marked heart.ai platform is officially launched at the PCR congress in Paris.
August 2022
LARALAB grows to 20 team members and plays the first LARALAB open.
September 2022
LARALAB celebrates the opening of the new headquarters in Munich.
February 2023
LARALAB launches advanced mitral valve workflow for investigational and research use by selected partners.
September 2023
LARALAB raises 5.7M € in a Series A2 round to further drive platform innovations together with partnering heart centers and device companies.
April 2024
LARALAB launches the powerful Gen2 Platform.
May 2024
LARALAB launches REC Rapid Eligibility check, capable of eliminating ineligible pathways in seconds.
October 2024
The Mitral Valve Module is now CE marked.
November 2024
LARALAB launches its new CE marked Aortic Valve Module.
February 2025
LARALAB unveils new heart.ai logo and branding.
April 2025
LARALAB's heart.ai platform receives FDA 510(k) clearance, covering mitral, tricuspid, aortic valves and cardiac chambers.
April 2025
LARALAB announces three selected partner registry studies, with Columbia University, Bad Oeynhausen and LMU Munich.
